Glenview Capital has reduced its holdings in CVS Health by 3.75 million shares following strong Q1 results and raised annual guidance, after the stock gained 80% since their initial investment in May 2024. Despite the reduction, CVS remains one of Glenview's three largest positions, reflecting confidence in the company's ongoing operational turnaround and long-term growth prospects. The fund plans no further adjustments, citing CVS's efforts to improve pharmacy services, medication access, and healthcare navigation as key factors supporting its positive outlook.
Aetna's latest survey shows U.S. healthcare providers' trust in payers increased to a score of 6.1 from 5.4, reflecting improved perceptions of payer reliability and communication. Providers highlight technology's role in reducing administrative task...
CVS Caremark announced a global settlement with the Federal Trade Commission (FTC) resolving all litigation related to rebate practices, pharmacy network contracting, and vertical integration. The agreement ends ongoing investigations and allows CVS ...
